With obesity affecting 40% of American adults, more employers are considering coverage for GLP-1 weight loss drugs. But these medications come with high costs. Here's what employers need to know about coverage trends, benefits, and considerations.
GLP-1 medications like Ozempic, Wegovy, and Zepbound have become some of the most talked-about drugs in healthcare. Originally developed to treat type 2 diabetes, these medications have proven remarkably effective for weight loss—helping patients lose an average of 12-21% of their body weight in clinical trials.
As obesity rates remain high and demand for these drugs grows, employers face an important question: Should they add GLP-1 coverage for weight loss to their health plans?
The answer isn't straightforward. While these medications offer real health benefits, they also come with substantial costs that are affecting employer budgets across the country. Here's what you need to know about GLP-1s, employer coverage trends, and the factors to consider when making this decision for your organization.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a hormone naturally produced in your gut. They work by reducing appetite, slowing digestion, and helping you feel fuller longer.
Common GLP-1 and related medications include:
Ozempic (semaglutide) – FDA-approved for type 2 diabetes and kidney disease; commonly prescribed off-label for weight loss
Wegovy (semaglutide) – FDA-approved for chronic weight management and cardiovascular risk reduction; pill version approved December 2025
Zepbound (tirzepatide) – FDA-approved for weight loss and obstructive sleep apnea
Mounjaro (tirzepatide) – FDA-approved for type 2 diabetes; same active ingredient as Zepbound
According to KFF, about 1 in 8 American adults (roughly 40 million people) are currently taking a GLP-1 medication for weight loss, diabetes, or another condition. Use is highest among adults ages 50-64.
Obesity remains a significant health challenge in the United States. According to CDC data:
About 40% of American adults have obesity (BMI of 30 or higher)
Nearly 10% have severe obesity (BMI of 40 or higher)
In 2024, 19 states had adult obesity rates at or above 35%—down from 23 the prior year.
The South (34.5%) and the Midwest (35.9%) have the highest regional obesity rates.
Obesity increases the risk of type 2 diabetes, heart disease, stroke, certain cancers, and other chronic conditions. For employers, this translates to higher healthcare costs, reduced productivity, and increased absenteeism. Research suggests annual productivity losses due to obesity range from $271 to $542 per employee, with absenteeism increasing up to seven extra days per year for employees with severe obesity.
According to KFF, 34% of non-elderly adults with employer-sponsored insurance (about 36 million people) have a BMI that would medically qualify them for a GLP-1 medication.
The 2025 KFF Employer Health Benefits Survey reveals a significant shift in how larger employers approach GLP-1 coverage for weight loss:
Coverage by employer size:
5,000+ employees: 43% now cover GLP-1s for weight loss (up from 28% in 2024)
1,000-4,999 employees: 30% cover GLP-1s for weight loss
200-999 employees: 16% cover GLP-1s for weight loss
The cost reality:
59% of very large employers (5,000+) say GLP-1 use for weight loss was higher than expected
66% of these employers say GLP-1s had a "significant" impact on prescription drug spending
One employer reported GLP-1s went from their 32nd highest drug cost to their #1 drug cost in a single year
Among employers with 200+ workers that don't currently cover GLP-1s for weight loss, only 1% say they're "very likely" to begin coverage in the next 12 months, while 67% say they're "not likely" to add coverage.
GLP-1 medications are expensive, though recent government deals and manufacturer programs are bringing prices down:
List prices (without insurance or discounts):
Ozempic: approximately $1,000/month
Wegovy: approximately $1,350/month
Zepbound: approximately $1,086/month
Net costs to employers (after rebates and discounts):
Approximately $617-$766 per month per employee
Direct-to-consumer cash prices (November 2025):
Ozempic/Wegovy: $349/month through Novo Nordisk ($199/month for first two months for new patients on lowest doses)
Zepbound: $299-$449/month through LillyDirect, depending on dose
TrumpRx pricing (launching early 2026):
Injectable GLP-1s: Average $350/month to start, expected to drop to $250/month within two years
Oral GLP-1 pills (if approved): Starting dose at $149/month
For context, U.S. prices remain 2-4 times higher than those in European countries, where monthly costs typically range from $83 to $144.
Improved employee health:
Obesity is a risk factor for diabetes, heart disease, stroke, and certain cancers. GLP-1 medications have demonstrated benefits beyond weight loss, including reductions in cardiovascular risk, kidney protection, and potential treatment for conditions such as sleep apnea and fatty liver disease. By supporting weight loss efforts, employers may help reduce long-term healthcare costs and address underlying health concerns before they become more serious.
Enhanced productivity:
Employees struggling with obesity-related health issues may experience increased sick days, reduced energy, and lower work performance. Effective weight management can help address these challenges, improving individual and overall organizational productivity.
Competitive advantage in hiring:
Comprehensive health benefits remain a key factor in attracting and retaining talent. According to KFF, 71% of large employers covering GLP-1s for weight loss say the benefit is "very important" or "somewhat important" to employee satisfaction. Even among employers that do not offer coverage, 45% say it would be important to employees.
Demonstrating commitment to employee wellness:
Offering coverage for medically effective weight loss treatments shows employees that their employer supports their health journey. This can increase engagement, loyalty, and participation in broader wellness initiatives.
Significant cost impact:
The financial reality is sobering. The Employee Benefit Research Institute estimates that GLP-1 coverage could increase employer premiums by up to 14%, even when access is limited to patients with the highest medical need. With average family coverage already reaching $26,993 in 2025 (up 6% from 2024), adding another significant cost driver requires careful consideration.
Higher-than-expected utilization:
Most employers who added GLP-1 coverage report that utilization exceeded expectations. Some employers found that employees who didn't previously seem to struggle with weight issues began requesting the medications. Managing demand while controlling costs is an ongoing challenge.
Adherence challenges:
According to Blue Cross Blue Shield research, nearly two-thirds of patients discontinue GLP-1 treatment before reaching the 12-week mark needed for meaningful weight loss. This raises questions about return on investment and whether employees will achieve lasting benefits.
Long-term use requirements:
These medications generally need to be taken continuously to maintain weight loss. Research shows that patients often regain weight when they stop taking GLP-1s. This means costs aren't a one-time investment but an ongoing expense.
Coverage changes by insurers:
Insurance coverage for GLP-1s is shifting. In July 2025, CVS Caremark removed Zepbound from its standard formulary, leaving over 97 million people without coverage for that specific medication. Over 28 million people still lack commercial insurance coverage for Wegovy. These coverage changes can create complications for employees who were relying on their benefits.
Many employers are implementing strategies to balance access with cost control:
Requiring participation in wellness programs:
About 34% of large employers that cover GLP-1s for weight loss require enrollees to meet with a dietitian, case manager, or therapist, or to participate in a lifestyle program as a condition of coverage. This helps ensure that employees take a comprehensive approach to weight management.
Restricting eligibility:
Some employers limit coverage to employees with higher BMIs or specific obesity-related medical conditions like diabetes. This focuses resources on those with the greatest medical need.
Adding utilization management:
Employers are implementing prior authorization requirements, time limits on coverage, and periodic re-evaluation requirements to manage utilization and costs.
Scaling back or eliminating coverage:
Some employers who initially offered broad GLP-1 coverage are now restricting it to medications for diabetes or other specific medical indications—not to weight loss alone. Others have eliminated weight loss coverage due to cost concerns.
If your organization is evaluating whether to add GLP-1 coverage for weight loss, consider these questions:
What's your budget reality? Can your organization absorb potential premium increases of several percentage points? How would this affect other benefits or employee cost-sharing?
What's your workforce profile? How many employees might be eligible for these medications? What's the potential demand?
What conditions would you require? Would you require participation in wellness programs, meeting with a dietitian, or specific BMI thresholds?
How does this fit your wellness strategy? Is this part of a broader approach to employee health that includes nutrition education, fitness programs, and other support?
What's your competitive landscape? Are competitors offering this benefit? Is it affecting your ability to recruit or retain employees?
What are the long-term implications? Since these medications often need to be taken continuously, are you prepared for ongoing costs rather than a one-time investment?
GLP-1 medications represent a genuine breakthrough in obesity treatment. They can help employees achieve meaningful weight loss and potentially reduce the risk of serious health conditions. At the same time, they come with real costs that are straining employer budgets.
There's no one-size-fits-all answer. The right decision depends on your organization's financial situation, workforce needs, competitive pressures, and overall approach to employee wellness. Weight-loss drugs are just one tool for addressing obesity—they work best as part of a holistic approach that includes nutrition, physical activity, and ongoing support.
As drug prices continue to evolve and new formulations (including oral pills) enter the market, the cost-benefit equation may shift. Employers who aren't ready to add coverage today may want to revisit the decision in the coming years.
Whether you're considering adding GLP-1 coverage or exploring other ways to enhance your employer-sponsored health plan, our experienced North Carolina agents can help. We work with employers of all sizes to find health insurance solutions that balance comprehensive coverage with budget realities.
Contact us today at 1-800-797-0327 to discuss your organization's health benefits needs. Our service is free, and we're here to help you make informed decisions about your employees' coverage.
How much do GLP-1 medications cost employers?
Net costs to employers (after rebates and discounts) typically range from $617 to $766 per employee per month. However, the total cost impact depends on the number of employees who use the benefit. Some employers report GLP-1s becoming their single largest drug expense.
What percentage of employers cover GLP-1s for weight loss?
According to the 2025 KFF Employer Health Benefits Survey, 43% of very large employers (5,000+ employees) cover GLP-1s for weight loss, up from 28% in 2024. Coverage rates are lower among smaller employers: 30% of firms with 1,000-4,999 employees and 16% of firms with 200-999 employees.
Do employees have to take GLP-1s forever?
Generally, yes. Research shows that patients often regain weight when they stop taking GLP-1 medications. This is an important consideration for employers, as it means coverage costs will be ongoing rather than a one-time expense.
What conditions can employers require for coverage?
About 34% of large employers covering GLP-1s for weight loss require employees to participate in a lifestyle program, meet with a dietitian or therapist, or meet specific BMI thresholds. These requirements help ensure employees take a comprehensive approach to weight management.
Are there alternatives to covering GLP-1s?
Yes. Some employers focus on covering GLP-1s only for diabetes and other medical indications (not weight loss alone) while investing in wellness programs, nutrition counseling, fitness benefits, and other weight management support. Bariatric surgery is another option that is often covered by insurance.
Will GLP-1 prices come down?
Prices are already declining through manufacturer discounts and government negotiations. The Trump administration's TrumpRx program (launching early 2026) aims to offer injectable GLP-1s at around $350/month, with prices expected to drop to $250/month within two years. New oral formulations may also increase competition and lower costs.